Evidence map›Paper›PMID 42331588›Full record

Trial reportBMJ open2026

Oral oxycodone versus sublingual buprenorphine for postoperative pain control after pelvic exenteration (PROSPER): a pilot, registry-embedded, multi-centre, double-blind, placebo-controlled, randomised controlled trial.

Charlotte Johnstone, Cherry Koh, Stephanie Mathieson, Daniel Steffens, Kate White, Paul Gray, Craig Harris, Alexander Heriot, Kaitlin Kramer, Chi Kin Law and 13 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Charlotte JohnstoneDepartment of Anaesthesia, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia charlotte.johnstone@sydney.edu.au.ORCID http://orcid.org/0000-0003-4312-5084
Cherry KohFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Stephanie MathiesonSydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Daniel SteffensFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Kate WhiteSydney Nursing School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-4763-1734
Paul GrayThe University of Queensland, Brisbane, Queensland, Australia.
Craig HarrisThe University of Queensland, Brisbane, Queensland, Australia.
Alexander HeriotDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Kaitlin KramerDepartment of Anaesthesia, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Chi Kin LawNHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Chung-Wei Christine LinSydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-6192-7238
Xiaoqiu LiuThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Gustavo MachadoFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8544-0448
Andrew McLachlanSydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0003-4674-0242
Jonathan PenmSydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-9606-7135
Bernhard RiedelThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2577-3918
Tarik SammourDepartment of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Robert SandersDepartment of Anaesthesia, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Michael SolomonFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Lilian WhiteheadSurgical Outcomes Research Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Des WinterDepartment of Colorectal Surgery, St Vincent's University Hospital, Dublin, Leinster, Ireland.
Jamie YoungDepartment of Critical Care, The University of Melbourne, Melbourne, Victoria, Australia.
Asad PatanwalaSydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to estimate the rate of recruitment of participants.

designThis is a pilot, multicentre, double-blind, placebo-controlled, randomised controlled trial of oral oxycodone and sublingual placebo vs sublingual buprenorphine and oral placebo for postoperative pain management for 7 days after pelvic exenteration.

settingPatients will be recruited from three metropolitan quaternary referral centres that offer advanced gastrointestinal surgery in Australia.

participantsThe inclusion criteria will be patients over the age of 18 years undergoing pelvic exenteration surgery and exclusion criteria are previous adverse events related to the study drugs, currently requiring monoamine oxidase inhibitor medications and if epidural analgesia is planned in the perioperative period.

interventionsEnrolled patients will undergo pelvic exenteration surgery and be initiated postoperatively on patient-controlled analgesia. In the postoperative period, when clinically appropriate to take oral medications, patients will be commenced on trial analgesia for 7 days. Participants will be randomised to receive either oral active oxycodone 5-10 mg up to 3 hourly as required (with sublingual placebo) or sublingual active buprenorphine 200-400 mcg 3 hourly as required (with oral placebo).

main outcome measuresThe primary outcome measure is the rate of recruitment over a 6-month period. Secondary outcomes include an assessment of missing data, protocol adherence and acceptability of the trial to participants. ETHICS AND DISSEMINATION: The trial received ethics approval from Sydney Local Health District, Royal Prince Alfred Hospital Human Research Ethics Committee (No: X25-0128 & 2025/ETH01058). The results of the study will be disseminated by publication and presentation at local annual scientific meetings in Australia. TRIAL REGISTRATION NUMBER: The study protocol is prospectively registered at the Australian New Zealand Clinical Trials Registry (ANZCTR) (www.anzctr.org.au; ACTRN12625000901404).

Indexed as

Analgesics, OpioidBuprenorphineOxycodonePelvic ExenterationPostoperative PainAdministration, OralAdministration, SublingualAdultAnalgesia, Patient-ControlledAustraliaDouble-Blind MethodFemaleHumansMaleMiddle AgedPain MeasurementAnalgesics, OpioidBuprenorphineOxycodoneCancer PainColorectal surgeryDrug TherapyPAIN MANAGEMENTPelvic PainProspective studies

Identifiers

PMID42331588
PMCPMC13289154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.